1. Kura Oncology's ziftomenib shows promising Phase 2 data in newly diagnosed AML patients and is nearing FDA Priority Review for relapsed/refractory cases; 2. The pipeline expands into combination therapies with encouraging early results; 3. Strong financial position ($703M cash) and partnership with Kyowa Kirin reduce dilution risks and support commercialization.